Jump on These 5 Ultra-High-Yield Pound-the-Table Stock Buys Now
24/7 Insights Wounded blue chip stocks can offer huge total return potential.
Buy The Drop On These 6% Dividend Value Picks
AI stocks like Nvidia, Super Micro Computer, and Dell Technologies are leading the market but may be in bubble territory. Value stocks like W.P. Carey and Bristol Myers Squibb offer beaten-down pri...
5 Stocks I Sold Due To "Fragile Stagflation" Risk
Fragile stagflation presents challenges for investors, with limited opportunities for good returns in stocks and bonds. It is likely markets will experience a lost decade in real terms when measure...
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold
Pfizer has a lot of new drugs on the market, but its stock has been beaten down. Johnson & Johnson stock is down even though both its medical technology and pharmaceutical businesses reported signi...
3 Warren Buffett Stocks to Buy Now: June 2024
Investors continue to look for the market to broaden before jumping in. They may be waiting awhile.
3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade
Pfizer stock has been beaten down so far that it offers a dividend yield above 6% at recent prices. Bristol Myers Squibb has been trading for the low multiple of about 7 times trailing free cash flow.
3 High-Yield Dividend Stocks for Income Now and Growth Later
The latest readings on inflation show some cooling, and stocks seem to like it. However, it's important to be clear about why investors feel bullish.
Why Bristol Myers Squibb Is A Top Socially Responsible Dividend Stock
Bristol Myers Squibb has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.8% yield, a...
Bristol Myers: Quality Fundamentals Suppressed By Interest Rates
Bristol Myers Squibb has solid fundamentals that have been clouded by the rise of interest rates. The company's revenue is at risk due to higher debt burdens and future patent expiry concerns, but ...
The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024
For many investors, especially those who are just building a portfolio, undervalued stocks under $50 hold significant appeal. Investors can start a significant position, in terms of shares owned, f...
Earn An 'Embarrassing' Amount Of Cash Flow From These Contrarian Picks
Amazon CEO Andy Jassy highlights key traits for success in a career professional, including working hard, being can-do, and following through on commitments. There are different paths to success, a...
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes
Treatment with Bristol Myers Squibb's immunotherapies Opdivo and Yervoy prior to surgery for patients whose skin cancer had spread to lymph nodes had better outcomes than those who did not get the ...
Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion
Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.
Related Companies